The content of this article is more than 5 years old. Please be aware that information provided may no longer be accurate, up-to-date, or relevant.
Alta Charo has been appointed to the National Academies committee asked by the Food and Drug Administration to consider the ethical issues related to mitochondrial modification of eggs, the first form of gene therapy to have multigenerational effects and to produce children with DNA from three different people.
Submitted by Law School News on January 5, 2015
This article appears in the categories: Activities & Scholarship
